TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06546267

Intervention type: RADIATION
Intervention: Image Guided Radiotherapy
Description: Patients treated with IGRT for Prostate cancer will be evaluated

Intervention type: RADIATION
Intervention: Image Guided Radiotherapy
Description: Patients treated with IGRT for Prostate cancer will be evaluated

Intervention type: RADIATION
Intervention: Image Guided Radiotherapy
Description: Patients treated with IGRT for Prostate cancer will be evaluated

Intervention type: RADIATION
Intervention: Image Guided Radiotherapy
Description: Patients treated with IGRT for Prostate cancer will be evaluated

Intervention type: RADIATION
Intervention: Intensity Modulated Radiotherapy
Description: Patients treated with IMRT for Prostate cancer will be evaluated

Intervention type: RADIATION
Intervention: Intensity Modulated Radiotherapy
Description: Patients treated with IMRT for Prostate cancer will be evaluated

Intervention type: RADIATION
Intervention: Intensity Modulated Radiotherapy
Description: Patients treated with IMRT for Prostate cancer will be evaluated

Intervention type: RADIATION
Intervention: Intensity Modulated Radiotherapy
Description: Patients treated with IMRT for Prostate cancer will be evaluated

Intervention type: RADIATION
Intervention: Stereotactic Body Radiotherapy
Description: Patients treated with SBRT for Prostate cancer will be evaluated

Intervention type: RADIATION
Intervention: Stereotactic Body Radiotherapy
Description: Patients treated with SBRT for Prostate cancer will be evaluated

Intervention type: RADIATION
Intervention: Stereotactic Body Radiotherapy
Description: Patients treated with SBRT for Prostate cancer will be evaluated

Intervention type: RADIATION
Intervention: Stereotactic Body Radiotherapy
Description: Patients treated with SBRT for Prostate cancer will be evaluated
Study: NCT05105698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemigliptin and dapagliflozin 50/10 mg film-coated tablet (Fasting)
Description: Subjects will check-in a night before investigational product administration, supervised for at least 8 hours overnight fasting prior to dosing and in-house stay until 24 hours post-dose.(fasting)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemigliptin and dapagliflozin 50/10 mg film-coated tablet (fed)
Description: Subjects will check-in a night before investigational product administration, supervised for at least 8 hours overnight fasting prior to dosing and in-house stay until 24 hours post-dose.(fed)
Study: NCT05123625

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reduce surgical procedures
Description: In the intervention group, investigators used a reductive approach. That is, for radical cystectomy, investigators did not perform pelvic lymph node dissection.
Study: NCT05337956

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block catheter
Description: All ESP blocks will be performed in lateral position after general anesthesia induction. ESPB will be performed under ultrasonographic guidance using a linear 6- to 10-MHz ultrasound probe. The linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to the T6-10 spinous process. The erector spinae muscles will be identiﬁed superﬁcial to the tip of the transverse process. A 21-gauge 10-cm needle will be inserted using an in-plane superior-to-inferior approach or an out of plane approach. The tip of the needle will be placed into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be conﬁrmed by visible ﬂuid spread lifting erector spinae muscle oﬀ the bony shadow of the transverse process on Ultrasonographic imaging. A total of 10-15 ml of 0.2% ropivacaine will be injected each side. A catheter will then be placed leaving 5 cm in place.
Study: NCT04916574

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Spray Containing Anti-SARS-CoV-2 Antibodies Derived from Bovine Colostrum
Description: Concentration of active substance on nasal mucosal surface in time

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Spray Containing Anti-SARS-CoV-2 Antibodies Derived from Bovine Colostrum
Description: Concentration of active substance on nasal mucosal surface in time
Study: NCT05332431

Intervention type: DEVICE
Intervention: Optical coherence tomography (OCT)
Description: Patient with different types of migraine and age and sex matched control group will be subjected to OCT in the ophthalmology department in Assiut University Hospital to assess the following parameters:~Optic nerve head parameters and retinal nerve fibre layer thickness and measuring macular thickness in migraine patients will be measured using optical coherence tomography (OCT) after pupillary dilatation. Retinal nerve fiber layer thickness included average thickness (360° measurement), temporal quadrant thickness (316-45°), superior quadrant thickness (46-135°), nasal quadrant thickness (136-225°) and inferior quadrant thickness (226-315°) will be measured by OCT.

Intervention type: DEVICE
Intervention: Optical coherence tomography (OCT)
Description: Patient with different types of migraine and age and sex matched control group will be subjected to OCT in the ophthalmology department in Assiut University Hospital to assess the following parameters:~Optic nerve head parameters and retinal nerve fibre layer thickness and measuring macular thickness in migraine patients will be measured using optical coherence tomography (OCT) after pupillary dilatation. Retinal nerve fiber layer thickness included average thickness (360° measurement), temporal quadrant thickness (316-45°), superior quadrant thickness (46-135°), nasal quadrant thickness (136-225°) and inferior quadrant thickness (226-315°) will be measured by OCT.
Study: NCT04908397

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-carnitine
Description: supplement provided twice a day for 2 weeks
Study: NCT04731389

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: internet-based cognitive-behavioral therapy
Description: Composed of 4 modules: the first module will address psychoeducation on dermatillomania, self-monitoring of symptoms and habit reversal techniques; the second module works with anxiety coping techniques (diaphragmatic breathing and muscle relaxation); module 3 addresses cognitive correction techniques, such as stopping thinking, analyzing evidence, reassigning severity and responsibilities; the last module reviews the techniques learned and addresses techniques for preventing symptom relapse. The modules will be applied by the patient in an online format, each module lasts an average of 30 minutes. The platform will send notice by email through automation tools, SMS or message by application to patients to remind them to complete 1 module per week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quality of life improving intervention
Description: consisting of videos with guidance on quality of life, with a total of 4 videos of 2 minutes, each being made available in 1 week, consisting of: guidance on sleep hygiene; guidance on healthy eating; guidelines on the practice of physical activity and guidelines on the excessive use of social networks.
Study: NCT05625321

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Group Weight Loss Classes
Description: Participants will be provided with educational materials on weight loss, and have opportunities to increase their exercise and make changes to their diet.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Group Weight Loss Classes
Description: Participants will be provided with educational materials on weight loss, and have opportunities to increase their exercise and make changes to their diet.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Gardening Intervention
Description: Participants will receive tools to establish their own home garden, increasing their access to fresh fruits and vegetables.
Study: NCT05664867

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mainstream Genetic Testing Model
Description: Mainstream Genetic Testing Model of Cancer Genetics Service Delivery
Study: NCT06350188

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental
Description: 15 patients ˃receive kinisio-tape ,2 session / week for 2 weeks. Followed by stretching exercises, they will be assessed pre and immediately post application, after two weeks and follow up after one month

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional
Description: 15 patients ˃ will receive ischemic pressure release followed by stretching exercises 2 session / week for 2 weeks, will be assessed pre and immediately post application, after two weeks and follow up after one month.
Study: NCT06011408

Intervention type: OTHER
Group type: OTHER
Intervention: TDtect
Description: Collecting video data on abnormal movement

Intervention type: OTHER
Group type: OTHER
Intervention: TDtect
Description: Collecting video data on abnormal movement
Study: NCT06451302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide, adriamycin, vincristine，Ifosfamide，etoposide
Description: The doses and intensity of chemotherapy vary according to risk stratification. Mainenance therapy is added to high-risk patients.
Study: NCT05355103

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational tool about epidural analgesia
Description: See arm description
Study: NCT05664867

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Standard of Care Model
Description: Enhanced Standard of Care Model of Cancer Genetic Service Delivery
Study: NCT04968158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg / Tramadol 50 mg
Description: One packet diluted in 100 ml of water, every 24 hours of 90 mg/50 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen 325 mg / Tramadol 37.5 mg
Description: One tablet, every 8 hours of 325 mg/ 37.5 m
Study: NCT05183945

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Localization needle
Description: A localization needle which is used for preoperative localization of lung nodules.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coil
Description: A coil which is used for preoperative localization of lung nodules.
Study: NCT05861596

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Participants suffered from acute stroke with dysphagia in single hospital who were determined by CT/MRI and clinical evaluation. The aim of this study is to compare the effects of rTMS, Neuromuscular electrical stimulation (NMES) and conventional swallowing therapy to those of sham rTMS, Neuromuscular electrical stimulation(NMES) and conventional swallowing therapy. One group will receive Neuromuscular electrical stimulation(NMES), to sham One group will receive Neuromuscular electrical stimulation(NMES),traditional swallowing therapy and rTMS therapy five times per week for 2 weeks ; Another group will receive Neuromuscular electrical stimulation(NMES) and traditional swallowing therapy with shame rTMS five times per week for 2 weeks. MEP character, FEES, degrees of dysphagia, FOIS, and SSA were used for evaluated swallowing function before the therapy and after 2 weeks therapy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation combined with conventional swallowing training
Description: Participants suffered from acute stroke with dysphagia in single hospital who were determined by CT/MRI and clinical evaluation. The aim of this study is to compare the effects of rTMS, Neuromuscular electrical stimulation (NMES) and conventional swallowing therapy to those of sham rTMS, Neuromuscular electrical stimulation(NMES) and conventional swallowing therapy. One group will receive Neuromuscular electrical stimulation(NMES), to sham One group will receive Neuromuscular electrical stimulation(NMES),traditional swallowing therapy and rTMS therapy five times per week for 2 weeks ; Another group will receive Neuromuscular electrical stimulation(NMES) and traditional swallowing therapy with shame rTMS five times per week for 2 weeks. MEP character, FEES, degrees of dysphagia, FOIS, and SSA were used for evaluated swallowing function before the therapy and after 2 weeks therapy.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Neuromuscular electrical stimulation combined with conventional swallowing training
Description: Participants suffered from acute stroke with dysphagia in single hospital who were determined by CT/MRI and clinical evaluation. The aim of this study is to compare the effects of rTMS, Neuromuscular electrical stimulation (NMES) and conventional swallowing therapy to those of sham rTMS, Neuromuscular electrical stimulation(NMES) and conventional swallowing therapy. One group will receive Neuromuscular electrical stimulation(NMES), to sham One group will receive Neuromuscular electrical stimulation(NMES),traditional swallowing therapy and rTMS therapy five times per week for 2 weeks ; Another group will receive Neuromuscular electrical stimulation(NMES) and traditional swallowing therapy with shame rTMS five times per week for 2 weeks. MEP character, FEES, degrees of dysphagia, FOIS, and SSA were used for evaluated swallowing function before the therapy and after 2 weeks therapy.
Study: NCT04662008

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tele-coaching
Description: This intervention arm will receive 4 one-to-one tele-coaching sessions facilitated by an advanced practice social worker. The sessions will take place over a 6-week period and will begin with a needs assessments to allow for tailoring of the intervention sessions. The sessions will include information and support in the areas of: general MS information, strategies for caring for a loved one with MS, MS and Covid (care strategies), caring for yourself, and planning for the future. The intervention will take place using Zoom videoconferencing technology or via telephone- per subject preference. In addition, all subjects will receive access to a study-specific website. The website will have links to publicly available information including general information about MS, online information, self-care, communication, caregiving, COVID-19, future planning.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Website
Description: This intervention arm will receive access to a study-specific website. The website will have links to publicly available information including: general information about MS, online information, self-care, communication, caregiving, COVID-19, future planning.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Website
Description: This intervention arm will receive access to a study-specific website. The website will have links to publicly available information including: general information about MS, online information, self-care, communication, caregiving, COVID-19, future planning.
Study: NCT05853146

Intervention type: DEVICE
Intervention: Oxitone 1000M
Description: World's First FDA-cleared Wrist-Sensor Pulse Oximetry Monitor
Study: NCT04847843

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Orientated Recovery Enhancement
Description: The MORE curriculum has been adapted for this intervention to address food intake behaviors and will provide training in mindfulness techniques to increase awareness of, and self-control over, cravings; reappraisal skills to promote emotion regulation and restructure motivations for highly palatable food intake; and savoring pleasant events and emotions to overcome defects in natural reward processing.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Intervention
Description: The curriculum will be based on the Diabetes Prevention Program's Prevent T2 for Life program, which is an evidence-based national healthful lifestyle maintenance intervention. This program includes training in healthful eating, meal planning, and recipe modification; time and stress management; adapting lifestyle habits for continued success during holidays, vacations, and other special situations; and relapse prevention.
Study: NCT06055179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiao Chai Hu Tang (XCHT)
Description: XCHT 9g, po qd, 3 days before each cycle of chemotherapy for 5 days, for 3 cycles of chemotherapy.
Study: NCT06130761

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pericapsular Nerve Group Block Combined With Lateral Femoral Cutaneous Nerve Block
Description: For PENG block transducer is placed in the transverse plane over the anterior inferior iliac spine (AIIS) and moved inferiorly to visualize the pubic ramus. The femoral artery and iliopubic eminence are visualized, and then, using an in-plane technique, a 22-gauge 50 mm needle is advanced from lateral to medial then 0.5 ml/kg of 0.25% bupivacaine is deposited between the psoas tendon anteriorly and pubic ramus posteriorly lifting it.~For LFCN the transducer is placed immediately inferior to the anterior superior iliac spine (ASIS), parallel to the inguinal ligament. The tensor fasciae lata muscle (TFLM) and sartorius muscle (SaM) are then identified. The nerve appears as a small hypoechoic oval structure with a hyperechoic rim between the TFLM and SaM in a short-axis view or superficial to the SaM. A 22-gauge 50 mm needle is inserted in-plane in a lateral-to-medial orientation through the subcutaneous tissue. A fascial pop may be felt as the needle tip enters the plane.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: trans muscular quadratus lumborum block
Description: With the patient in the lateral position, after standard sterilization of skin and probe identify 3 layers of the abdomen. The transversus abdominis is traced more posteriorly until the transversus aponeurosis. usually we can find the peritoneum curves away from the muscles from anterior to posterior . Tilting the probe slightly caudal into the pelvis thus improves the view of the retroperitoneal fat and the tapered end of transversus aponeurosis. QL is usually identified medial to the aponeurosis of transversus abdominis muscle vertically attached above the iliac crest. A 22-gauge 50 mm needle will be inserted in the plane from the posterior edge of the convex probe through the QL in an anteromedial direction. The needle tip will be placed between the PM muscle and the QL muscle and the local anesthetic will be injected into the fascial plane after aspiration test is negative. A volume 0.5 ml/kg of 0.25% bupivacaine is injected with maximum dose 2.5mg per kg of bupivacaine.
Study: NCT06055179

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 9g, po qd, 3 days before each cycle of chemotherapy for 5 days, for 3 cycles of chemotherapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Irinotecan regimen
Description: Patients will receive 3 cycles of irinotecan chemotherapy. FOLFIRI regimen:irinotecan (180 mg/m2) intravenous (IV) for over 90 minutes on Day 1. Folinic acid (400 mg/m2) IV over 2 hours on Day 1. 5-fluorouracil (5-FU) IV bolus (400 mg/m2) over 5 minutes on Day 1, followed by 5-FU (2400 mg/m2) IV continuously for 46-48 hours. Every 2 weeks.~mXELIRI regimen:irinotecan (200 mg/m2) intravenous (IV) for over 90 minutes on Day 1. Capecitabine (800 mg/m²) PO bid on day 1-14. Every 3 weeks.~CapIRI regimen:irinotecan (180 mg/m2) intravenous (IV) for over 90 minutes on Day 1. Capecitabine (1000 mg/m²) PO bid on day 1-14. Every 3 weeks.~FOLFOXIRI regimen:irinotecan (165 mg/m2) intravenous (IV) for over 90 minutes on Day 1. Oxaliplatin (85 mg/m2) intravenous (IV) for over 2 hours on Day 1.Folinic acid (400 mg/m2) IV over 2 hours on Day 1, followed by 5-FU (2400 - 3200 mg/m2) IV continuously for 48 hours. Every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan regimen
Description: Patients will receive 3 cycles of irinotecan chemotherapy. FOLFIRI regimen:irinotecan (180 mg/m2) intravenous (IV) for over 90 minutes on Day 1. Folinic acid (400 mg/m2) IV over 2 hours on Day 1. 5-fluorouracil (5-FU) IV bolus (400 mg/m2) over 5 minutes on Day 1, followed by 5-FU (2400 mg/m2) IV continuously for 46-48 hours. Every 2 weeks.~mXELIRI regimen:irinotecan (200 mg/m2) intravenous (IV) for over 90 minutes on Day 1. Capecitabine (800 mg/m²) PO bid on day 1-14. Every 3 weeks.~CapIRI regimen:irinotecan (180 mg/m2) intravenous (IV) for over 90 minutes on Day 1. Capecitabine (1000 mg/m²) PO bid on day 1-14. Every 3 weeks.~FOLFOXIRI regimen:irinotecan (165 mg/m2) intravenous (IV) for over 90 minutes on Day 1. Oxaliplatin (85 mg/m2) intravenous (IV) for over 2 hours on Day 1.Folinic acid (400 mg/m2) IV over 2 hours on Day 1, followed by 5-FU (2400 - 3200 mg/m2) IV continuously for 48 hours. Every 2 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Raloxifene
Description: Raloxifene 60mg po, used as probe for pharmacokinetic testing, on Day 3 (the day before chemotherapy), for 3 cycles of chemotherapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Raloxifene
Description: Raloxifene 60mg po, used as probe for pharmacokinetic testing, on Day 3 (the day before chemotherapy), for 3 cycles of chemotherapy.
Study: NCT05843825

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical placement of dental implants
Description: Three dental implants were placed (one anterior in midline area and two posterior at first molar area).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical placement of dental implants
Description: Three dental implants were placed (one anterior in midline area and two posterior at first molar area).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Overdenture supported by locator attachment system
Description: Implants were loaded after three months by using locator attachments.~Control group:Iocator attachments picked up using block out spacer.~Study group:Iocator attachments picked up without using block out spacer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Overdenture supported by locator attachment system
Description: Implants were loaded after three months by using locator attachments.~Control group:Iocator attachments picked up using block out spacer.~Study group:Iocator attachments picked up without using block out spacer